Moore Matthew Richard 4
4 · Arcutis Biotherapeutics, Inc. · Filed May 3, 2024
Insider Transaction Report
Form 4
Moore Matthew Richard
SVP and Chief Business Officer
Transactions
- Award
Common Stock
2024-05-01+4,166→ 150,186 total - Sale
Common Stock
2024-05-02$8.74/sh−4,681$40,902→ 145,505 total
Footnotes (4)
- [F1]Represents Restricted Stock Units ("RSUs"), initial grant on February 22, 2024, that were subject to a performance-based vesting condition, that was determined to be satisfied on the Vesting Commencement Date, May 1, 2024.
- [F2]The RSUs will vest in twelve equal quarterly installments on the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- [F3]Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the RSUs, the shares were sold upon the vesting of the RSUs solely to cover applicable tax withholding.
- [F4]The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.